KR101282191B1 - 신생물성 질환을 치료하는 조성물 및 방법 - Google Patents

신생물성 질환을 치료하는 조성물 및 방법 Download PDF

Info

Publication number
KR101282191B1
KR101282191B1 KR1020077015299A KR20077015299A KR101282191B1 KR 101282191 B1 KR101282191 B1 KR 101282191B1 KR 1020077015299 A KR1020077015299 A KR 1020077015299A KR 20077015299 A KR20077015299 A KR 20077015299A KR 101282191 B1 KR101282191 B1 KR 101282191B1
Authority
KR
South Korea
Prior art keywords
cancer
pharmaceutical composition
compound
formula
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020077015299A
Other languages
English (en)
Korean (ko)
Other versions
KR20080003306A (ko
Inventor
케네스 씨. 앤더슨
다마인더 차우한
Original Assignee
다나-파버 캔서 인스티튜트 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다나-파버 캔서 인스티튜트 인크. filed Critical 다나-파버 캔서 인스티튜트 인크.
Publication of KR20080003306A publication Critical patent/KR20080003306A/ko
Application granted granted Critical
Publication of KR101282191B1 publication Critical patent/KR101282191B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020077015299A 2004-12-03 2005-12-02 신생물성 질환을 치료하는 조성물 및 방법 Expired - Lifetime KR101282191B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63316104P 2004-12-03 2004-12-03
US60/633,161 2004-12-03
PCT/US2005/043668 WO2006060676A1 (en) 2004-12-03 2005-12-02 Compositions and methods for treating neoplastic diseases

Publications (2)

Publication Number Publication Date
KR20080003306A KR20080003306A (ko) 2008-01-07
KR101282191B1 true KR101282191B1 (ko) 2013-07-08

Family

ID=36118298

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077015299A Expired - Lifetime KR101282191B1 (ko) 2004-12-03 2005-12-02 신생물성 질환을 치료하는 조성물 및 방법

Country Status (17)

Country Link
US (5) US20070225350A1 (OSRAM)
EP (1) EP1830838B1 (OSRAM)
JP (3) JP5676071B2 (OSRAM)
KR (1) KR101282191B1 (OSRAM)
CN (2) CN101155582B (OSRAM)
AU (1) AU2005311709B2 (OSRAM)
BR (1) BRPI0517135B1 (OSRAM)
CA (1) CA2588923C (OSRAM)
DK (1) DK1830838T3 (OSRAM)
ES (1) ES2396762T3 (OSRAM)
IL (3) IL183506A (OSRAM)
MX (1) MX2007006526A (OSRAM)
NZ (1) NZ555439A (OSRAM)
PL (1) PL1830838T3 (OSRAM)
SG (1) SG157365A1 (OSRAM)
WO (1) WO2006060676A1 (OSRAM)
ZA (1) ZA200704402B (OSRAM)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
WO2002047610A2 (en) * 2000-11-16 2002-06-20 The Regents Of The University Of California Marine actinomycete taxon for drug and fermentation product dicovery
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
AU2004253478A1 (en) * 2003-06-20 2005-01-13 Nereus Pharmaceuticals, Inc. Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
US8217072B2 (en) * 2003-06-20 2012-07-10 The Regents Of The University Of California Salinosporamides and methods for use thereof
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
US7276530B2 (en) * 2004-04-30 2007-10-02 Nereus Pharmaceuticals, Inc. [3.2.0] Heterocyclic compounds and methods of using the same
EP1830838B1 (en) * 2004-12-03 2012-10-03 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating neoplastic diseases
CA2590334A1 (en) * 2004-12-03 2006-06-08 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
CN101495116A (zh) 2005-03-22 2009-07-29 哈佛大学校长及研究员协会 蛋白降解病症的治疗
EP1951226A2 (en) * 2005-11-04 2008-08-06 The Regents of the University of California Methods of sensitizing cancer to therapy-induced cytotoxicity
EP2010168B1 (en) 2006-02-14 2014-04-16 The President and Fellows of Harvard College Histone deacetylase inhibitors
JP5441416B2 (ja) 2006-02-14 2014-03-12 プレジデント アンド フェロウズ オブ ハーバード カレッジ 二官能性ヒストンデアセチラーゼインヒビター
NZ572026A (en) 2006-04-06 2011-12-22 Nereus Pharmaceuticals Inc Total synthesis of salinosporamide a and analogs thereof
CN101484156B (zh) 2006-05-03 2015-11-25 哈佛大学校长及研究员协会 组蛋白脱乙酰基酶和微管蛋白脱乙酰基酶抑制剂
US7824698B2 (en) * 2007-02-02 2010-11-02 Nereus Pharmaceuticals, Inc. Lyophilized formulations of Salinosporamide A
WO2008124699A1 (en) * 2007-04-06 2008-10-16 Nereus Pharmaceuticals, Inc. A method of using proteasome inhibitors in combination with histone deacetylase inhibitors to treat cancer
US20080280968A1 (en) * 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
CN102015721A (zh) 2008-03-07 2011-04-13 尼瑞斯药品公司 Salinosporamide a及其类似物的全合成
US7910616B2 (en) * 2008-05-12 2011-03-22 Nereus Pharmaceuticals, Inc. Proteasome inhibitors
CN102123708A (zh) * 2008-06-06 2011-07-13 大学健康网络 用于治疗恶性血液疾病的8-羟基喹啉衍生物
RU2515611C2 (ru) 2008-07-23 2014-05-20 Президент Энд Феллоуз Оф Гарвард Колледж Ингибиторы деацетилазы и их применение
WO2010019227A1 (en) * 2008-08-13 2010-02-18 George Mason Intellectual Properties, Inc. Ex vivo therapeutic screening of living bone marrow cells for multiple myeloma
WO2010099601A1 (en) * 2009-03-05 2010-09-10 University Health Network Use of 5ahq and bortezomib for the treatment of hematological diseases
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
US10475142B2 (en) 2011-12-30 2019-11-12 Elwha Llc Evidence-based healthcare information management protocols
US10528913B2 (en) 2011-12-30 2020-01-07 Elwha Llc Evidence-based healthcare information management protocols
US10552581B2 (en) 2011-12-30 2020-02-04 Elwha Llc Evidence-based healthcare information management protocols
US20130173298A1 (en) 2011-12-30 2013-07-04 Elwha LLC, a limited liability company of State of Delaware Evidence-based healthcare information management protocols
US10679309B2 (en) 2011-12-30 2020-06-09 Elwha Llc Evidence-based healthcare information management protocols
US10559380B2 (en) 2011-12-30 2020-02-11 Elwha Llc Evidence-based healthcare information management protocols
CN104884637A (zh) * 2012-11-05 2015-09-02 普隆奈治疗公司 利用生物标志物通过bcl2表达的调节治疗癌症的方法
AU2016349833A1 (en) * 2015-11-06 2018-05-24 Accuitis Pharmaceuticals, Inc. Use of proteasome inhibitors to treat ocular disorders
US10703760B2 (en) 2016-08-19 2020-07-07 Celgene International Ii Sàrl Morphic forms of marizomib and uses thereof
JP2020505470A (ja) * 2017-01-31 2020-02-20 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ＮＧｌｙ１を阻害する薬剤及びその使用方法
JP7498475B2 (ja) * 2020-01-31 2024-06-12 株式会社セラバイオファーマ 多発性骨髄腫の治療剤
CN113750215B (zh) * 2021-09-24 2023-06-23 暨南大学 用于治疗肿瘤的联合药物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040138196A1 (en) * 2002-06-24 2004-07-15 William Fenical Salinosporamides and methods for use thereof

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5276182A (en) 1990-07-09 1994-01-04 The Dow Chemical Company Process for preparing polyurea oligomers
DE4039602A1 (de) 1990-12-12 1992-06-17 Bauer Kurt Heinz Prof Dr Pharmazeutische formulierungen
KR100221695B1 (ko) 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5653962A (en) 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
EP0674510B1 (en) 1992-11-27 1998-08-05 Napro Biotherapeutics, Inc. Injectable composition comprising paclitaxel
US5654286A (en) 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
WO1995009626A1 (en) 1993-10-01 1995-04-13 Syntex (U.S.A.) Inc. Mycophenolate mofetil high dose oral suspensions
US5707641A (en) 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6838477B2 (en) 1995-04-12 2005-01-04 President And Fellows Of Harvard College Lactacystin analogs
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
CA2281224A1 (en) 1997-02-15 1998-08-20 Proscript, Inc. Treatment of infarcts through inhibition of nf-kappab
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
DK1004573T3 (da) 1997-08-04 2003-03-03 Nihon Nohyaku Co Ltd Aryloxyanilinderivater
US6133308A (en) 1997-08-15 2000-10-17 Millennium Pharmaceuticals, Inc. Synthesis of clasto-lactacystin beta-lactone and analogs thereof
HUP0002724A3 (en) 1997-08-15 2001-04-28 Millennium Pharm Inc Clasto-lactacystin betha-lactone, analogs and intermediates thereof, process for their preparation and pharmaceutical compositions containing them
US20010051654A1 (en) 1997-09-25 2001-12-13 Elliott Peter J. Treatment of inflammatory and autoimmune diseases
JP2001517631A (ja) 1997-09-25 2001-10-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症疾患および自己免疫疾患を治療するためのプロテアソーム阻害剤、ユビキチン経路阻害剤、またはユビキチンプロテアソーム経路を介したＮＦ−κＢの活性化に干渉する剤
US6831057B2 (en) 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
EP2201945B1 (en) 1997-11-21 2013-03-06 Purdue Neuroscience Company Use of substituted 2-aminoacetamides for treating or ameliorating anxiety
US6617171B2 (en) 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6333323B1 (en) 1998-03-26 2001-12-25 Shionogi & Co., Ltd. Indole derivatives with antiviral activity
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
KR20010080267A (ko) 1998-10-20 2001-08-22 밀레니엄 파머슈티컬스 인코퍼레이티드 프로테아솜 억제제 약물 작용을 모니터링하는 방법
FR2784988B1 (fr) 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20020049157A1 (en) 1999-08-25 2002-04-25 Jiangping Wu Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
EP2305291A1 (de) 2000-10-12 2011-04-06 ViroLogik GmbH Verwendung von Proteasome Hemmern zur Behandlung von HIV Infektionen
WO2002047610A2 (en) 2000-11-16 2002-06-20 The Regents Of The University Of California Marine actinomycete taxon for drug and fermentation product dicovery
WO2003084551A1 (de) 2002-04-05 2003-10-16 Viromics Gmbh Mittel zur behandlung von flaviviridae-infektionen
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
EP1565193B1 (en) 2002-11-06 2013-04-24 Dana-Farber Cancer Institute, Inc. Compositions for treating cancer using proteasome inhibitor PS-341
ES2336562T3 (es) 2003-02-14 2010-04-14 Intermed Discovery Gmbh Heterociclos sustituidos.
AU2004253478A1 (en) 2003-06-20 2005-01-13 Nereus Pharmaceuticals, Inc. Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
US8217072B2 (en) 2003-06-20 2012-07-10 The Regents Of The University Of California Salinosporamides and methods for use thereof
WO2005094423A2 (en) 2004-02-26 2005-10-13 President And Fellows Of Harvard College Selective inhibition of proteasomes of tuberculosis and other bacteria
US7371875B2 (en) 2004-03-12 2008-05-13 Miikana Therapeutics, Inc. Cytotoxic agents and methods of use
US7183417B2 (en) 2004-04-09 2007-02-27 President And Fellows Of Harvard College Simple stereocontrolled synthesis of salinosporamide A
WO2005099687A2 (en) 2004-04-09 2005-10-27 President And Fellows Of Harvard College Analogs of salinosporamide a
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
US7276530B2 (en) 2004-04-30 2007-10-02 Nereus Pharmaceuticals, Inc. [3.2.0] Heterocyclic compounds and methods of using the same
US20060264495A1 (en) 2004-04-30 2006-11-23 Michael Palladino Methods of using [3.2.0] heterocyclic compounds and analogs thereof
KR20070041742A (ko) 2004-07-12 2007-04-19 바이엘 크롭사이언스 아게 살진균제 및 살충제로서의 치환된 2-피롤리돈 유도체
WO2006060819A2 (en) 2004-12-03 2006-06-08 The Regents Of The University Of California Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells
EP1830838B1 (en) 2004-12-03 2012-10-03 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating neoplastic diseases
WO2006060609A1 (en) 2004-12-03 2006-06-08 Honeywell International Inc. Gas jet control for inertial measurement unit
CA2590334A1 (en) * 2004-12-03 2006-06-08 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
WO2006118973A2 (en) 2005-04-29 2006-11-09 Nereus Pharmaceuticals, Inc. Methods of using heterobyclic compounds for treatment of rectal cancer
WO2006124902A2 (en) 2005-05-16 2006-11-23 Sloan-Kettering Institute For Cancer Research Synthesis of salinosporamide a and analogues thereof
WO2007021897A1 (en) 2005-08-10 2007-02-22 President And Fellows Of Harvard College Analogs of salinosporamide a
US7572606B1 (en) 2005-09-09 2009-08-11 Nereus Pharmaceuticals, Inc. Biosyntheses of salinosporamide A and its analogs and related methods of making salinosporamide A and its analogs
US7465720B2 (en) 2005-09-12 2008-12-16 President And Fellows Of Harvard College Proteasome inhibiting β-lactam compounds
EP1951226A2 (en) 2005-11-04 2008-08-06 The Regents of the University of California Methods of sensitizing cancer to therapy-induced cytotoxicity
GB0605217D0 (en) 2006-03-15 2006-04-26 Novartis Ag Method and compositions for assessing acute rejection
NZ572026A (en) 2006-04-06 2011-12-22 Nereus Pharmaceuticals Inc Total synthesis of salinosporamide a and analogs thereof
WO2007130404A1 (en) 2006-05-03 2007-11-15 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof for the treatment of lung cancer
DE102006026464A1 (de) 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
US8088923B2 (en) 2006-07-07 2012-01-03 The Texas A&M University System Cyclic-fused beta-lactones and their synthesis
US20080280968A1 (en) 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
US8394816B2 (en) 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
CN102015721A (zh) 2008-03-07 2011-04-13 尼瑞斯药品公司 Salinosporamide a及其类似物的全合成
US7910616B2 (en) 2008-05-12 2011-03-22 Nereus Pharmaceuticals, Inc. Proteasome inhibitors
US8772724B2 (en) 2011-01-05 2014-07-08 Intel-Ge Care Innovations Llc Low power, inexpensive velocity detection using a PIR array

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040138196A1 (en) * 2002-06-24 2004-07-15 William Fenical Salinosporamides and methods for use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Angewandte Chemie. 2003. Vol. 42, No. 3, pp. 355-357 *
Angewandte Chemie. 2003. Vol. 42, No. 3, pp. 355-357*

Also Published As

Publication number Publication date
US10610517B2 (en) 2020-04-07
HK1113462A1 (en) 2008-10-03
JP2015028089A (ja) 2015-02-12
BRPI0517135A (pt) 2008-09-30
CN103230394B (zh) 2016-04-20
DK1830838T3 (da) 2013-01-21
MX2007006526A (es) 2007-09-19
IL183506A0 (en) 2007-10-31
KR20080003306A (ko) 2008-01-07
US20230210817A1 (en) 2023-07-06
NZ555439A (en) 2010-12-24
AU2005311709B2 (en) 2011-07-28
JP5963830B2 (ja) 2016-08-03
ES2396762T3 (es) 2013-02-26
CA2588923A1 (en) 2006-06-08
US8722724B2 (en) 2014-05-13
US20140349965A1 (en) 2014-11-27
JP5837469B2 (ja) 2015-12-24
IL183506A (en) 2015-10-29
CA2588923C (en) 2015-02-03
CN103230394A (zh) 2013-08-07
EP1830838A1 (en) 2007-09-12
AU2005311709A1 (en) 2006-06-08
EP1830838B1 (en) 2012-10-03
CN101155582A (zh) 2008-04-02
BRPI0517135B1 (pt) 2022-04-19
IL236426B (en) 2019-11-28
JP2008521928A (ja) 2008-06-26
JP2012236862A (ja) 2012-12-06
IL236426A0 (en) 2015-02-26
ZA200704402B (en) 2008-07-30
WO2006060676A1 (en) 2006-06-08
PL1830838T3 (pl) 2013-07-31
JP5676071B2 (ja) 2015-02-25
US20200206190A1 (en) 2020-07-02
US20070225350A1 (en) 2007-09-27
IL241756A0 (en) 2015-11-30
CN101155582B (zh) 2013-04-24
SG157365A1 (en) 2009-12-29
US20090036390A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
KR101282191B1 (ko) 신생물성 질환을 치료하는 조성물 및 방법
Chauhan et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
KR20200096141A (ko) 스트렙토니그린 및 항암제를 포함하는 대장암 예방 또는 치료용 약학적 조성물
JP2002508321A (ja) 抗腫瘍薬としての使用のための多触媒性プロテアーゼ阻害剤
Jing et al. Trifluoperazine synergistically potentiates bortezomib-induced anti-cancer effect in multiple myeloma via inhibiting P38 MAPK/NUPR1
CN110538172B (zh) 铁死亡抑制剂在制备治疗金诺芬肝毒性的药物中的应用
AU2023231023A1 (en) Treatment of clear cell renal cell carcinoma
CN116850289A (zh) Plk4靶向药物在治疗对铂类药物耐药型肿瘤中的应用
HK1113462B (en) Compositions and methods for treating neoplastic diseases
KR102387565B1 (ko) 스트렙토니그린 및 항암제를 모두 포함하는 암 예방 또는 치료용 약학적 조성물
Helson et al. 564 In vitro cytotoxic activity of NBT-272, a novel quassinoid analog
Meco et al. 562 The combination of ET-743 and Irinotecan is active in preclinical models in rhabdomyosarcoma
Chauhan et al. Targeting Cell-Death Pathways in Multiple Myeloma: Therapeutic Implications
MXPA06009577A (en) Antitumor agent
HK1133833A (en) Composition for the treatment of resistant cancers comprising oridonin

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070703

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20101104

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120820

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20130329

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20130628

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20130701

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20160527

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20160527

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20170615

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20170615

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20180615

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20180615

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20190614

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20190614

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20200617

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20210527

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20220517

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20240522

Start annual number: 12

End annual number: 12